On August 14, 2023, Atossa Therapeutics (NASDAQ: ATOS) unveiled its financial results for the six months ending June 30, 2023. The company recorded a net loss of $16,111, marking a significant increase compared to the net loss of $11,457 incurred during the same period in 2022.
Breaking down the figures further, Atossa Therapeutics reported a quarterly loss of $(0.08) per share, representing a 60% decrease in losses compared to $(0.05) per share reported during the corresponding quarter last year.
Investors eagerly await the upcoming earnings report from Atossa Therapeutics, scheduled for release on August 15, 2023. This report will provide further insights into the company’s financial performance and potentially shed light on future prospects.
Atossa Therapeutics, Inc.
Updated on: 07/12/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
5:00 AM (UTC)
Date:07 December, 2023
|Analyst / firm||Rating|
ATOS Stock Performance on August 14, 2023: Stable but with Negative Earnings Growth
ATOS stock had a mixed performance on August 14, 2023. According to data from CNN Money, the stock opened at $1.04 and had a day’s range of $1.01 to $1.08. The volume traded for the day was 385,168 shares, which is lower than the average volume of 757,062 shares over the past three months.
ATOS, with a market capitalization of $133.0 million, is a company in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The earnings growth for ATOS has been negative in recent years, with a decline of 20.83% last year and 14.29% expected for this year.
The price-to-earnings (P/E) ratio for ATOS is not provided (NM), and the price/book ratio is 1.13, indicating that the stock may be trading at a slight premium compared to its book value.
Looking at the performance of ATOS stock on August 14, 2023, it remained relatively stable compared to some other stocks in the sector and industry. CATXPerspective Therapeu… saw a small increase of 0.13%, while CDXCChromadex Corp experienced a decline of 1.24%. OGIOrganiGram Holdings had a larger decrease of 2.21%.
ATOS reported its last financial results on August 14, 2023. The company is expected to report a loss per share of $0.06 for this quarter. In the previous year, ATOS had an annual revenue of $0.00 and a net loss of $27.0 million.
ATOS does not have any executives listed, and its corporate headquarters are located in Seattle, Washington.
Overall, the performance of ATOS stock on August 14, 2023, was relatively stable. The company’s earnings growth has been negative in recent years, and it is expected to report a loss for the current quarter. Investors should closely monitor the company’s financial performance and market trends before making any investment decisions.
ATOS Stock Price Forecast: Potential Increase of 340.48% According to Analysts
ATOS stock experienced a significant increase in its target price on August 14, 2023. According to CNN Money, two analysts have offered their 12-month price forecasts for the stock. The median target price is $4.63, with a high estimate of $5.25 and a low estimate of $4.00. This indicates a potential increase of 340.48% from the last recorded price of $1.05.
The consensus among the two polled investment analysts is to buy the stock, which has remained steady since July. The current quarter’s earnings per share for ATOS stock is -$0.06, indicating a loss. However, the sales for this quarter are reported to be $0.00. These figures suggest that the company may be in a transitional phase or undergoing significant investments.
Investors should consider the target price forecasts and the buy rating from analysts before making any investment decisions. It is also crucial to conduct further research and analysis to gain a comprehensive understanding of Atossa Therapeutics Inc’s financial health, market position, and potential catalysts for growth.
As of August 14, 2023, investors can monitor the stock’s performance closely to see if it aligns with the analysts’ forecasts and if any significant news or events impact the stock’s trajectory. Additionally, it would be prudent to keep an eye on the company’s quarterly earnings reports to assess its financial performance and track any improvements or setbacks.
In conclusion, Atossa Therapeutics Inc’s stock performance on August 14, 2023, suggests positive sentiment among analysts, with a median target price of $4.63 and a potential increase of 340.48% from the last recorded price. However, investors should conduct thorough research and analysis before making any investment decisions, considering factors such as the company’s financial health and market conditions.